News

Medical Dialogues8h
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...